Literature DB >> 10878731

The variation in anti-ENA characteristics between different ethnic populations with systemic lupus erythematosus over a 10-year period.

C M Tench1, D A Isenberg.   

Abstract

OBJECTIVE: To assess how anti-ENA characteristics change in patients with systemic lupus erythematosus from different ethnic backgrounds over a 10-year period follow-up study.
RESULTS: There were 61 patients, of whom 37 were Caucasian, 12 were Asian and 12 were Afro-Caribbean. At the first available bleed 12/37 (32%) Caucasians were anti-ENA positive compared to 6/12 (50%) Asians and 9/12 (75%) of Afro-Caribbeans (Chi-squared P=0.01 for Caucasian vs Afro-Caribbean) and these proportions remained essentially unchanged after 10 y of follow-up. However, over the 10 y of follow-up anti-ENA patterns did change, with anti-Ro being the commonest antibody pattern to emerge and anti-Ro/La the commonest antibody pattern to disappear. There were 20/37(54%) Caucasians, 1/12(8%) Afro-Caribbeans and 5/12(42%) Asians who remained negative for anti-ENA throughout the 10-year follow-up (Chi-squared P=0.03 for Caucasian vs Afro-Caribbean).
CONCLUSION: Anti-ENA were more commonly found in the Afro-Caribbean than the Caucasian population. The commonest patterns of anti-ENA differ between ethnic groups and, over a 10-year period, anti-ENA patterns in individual patients changed in a significant number of individuals. However, Caucasians were more likely to remain anti-ENA negative over 10 y of follow-up than Afro-Caribbeans.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10878731     DOI: 10.1191/096120300678828451

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  8 in total

1.  Immune function in healthy inner-city children.

Authors:  J A Bartlett; A R Goldklang; S J Schleifer; S E Keller
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

2.  Longitudinal anti-nuclear antibody (ANA) seroconversion in systemic lupus erythematosus: a prospective study of Swedish cases with recent-onset disease.

Authors:  M Frodlund; J Wetterö; C Dahle; Ö Dahlström; T Skogh; J Rönnelid; C Sjöwall
Journal:  Clin Exp Immunol       Date:  2019-12-19       Impact factor: 4.330

Review 3.  Evolving story of autoantibodies in systemic lupus erythematosus.

Authors:  David S Pisetsky
Journal:  J Autoimmun       Date:  2019-12-04       Impact factor: 7.094

4.  B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response.

Authors:  Kristine P Ng; Geraldine Cambridge; Maria J Leandro; Jonathan C W Edwards; Michael Ehrenstein; David A Isenberg
Journal:  Ann Rheum Dis       Date:  2007-04-05       Impact factor: 19.103

Review 5.  New insights into the role of antinuclear antibodies in systemic lupus erythematosus.

Authors:  David S Pisetsky; Peter E Lipsky
Journal:  Nat Rev Rheumatol       Date:  2020-09-03       Impact factor: 20.543

6.  Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden.

Authors:  Catharina Eriksson; Heidi Kokkonen; Martin Johansson; Göran Hallmans; Göran Wadell; Solbritt Rantapää-Dahlqvist
Journal:  Arthritis Res Ther       Date:  2011-02-22       Impact factor: 5.156

Review 7.  Translating epigenetics into clinic: focus on lupus.

Authors:  Zijun Wang; Christopher Chang; Mou Peng; Qianjin Lu
Journal:  Clin Epigenetics       Date:  2017-08-02       Impact factor: 6.551

8.  The Use of Poly-L-Lysine as a Capture Agent to Enhance the Detection of Antinuclear Antibodies by ELISA.

Authors:  Nancy A Stearns; Shuxia Zhou; Michelle Petri; Steven R Binder; David S Pisetsky
Journal:  PLoS One       Date:  2016-09-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.